Citigroup Maintains Buy, $48 Target on Endo Pharmaceuticals

Citigroup reiterates its Buy rating and $48 target price on Endo Pharmaceuticals ENDP as it looks at core products and pricing trends for the week ending 12/16/11. Citigroup notes on the company's Lidoderm: "~$1,090M Annual Run Rate Implied by 4-Week Average TRx's vs. Our 2011E Sales of ~$806M (+3%). 4Q11 QTD TRx growth is +2% vs. +1%/+1%/+5%/+1% in 3Q11/2Q11/1Q11/4Q10. Lidoderm represents ~23% of ‘12E sales, down from 52%in ‘09. Endo expects low single-digit '11 growth (vs. our +1% est.) supported by favorable patient demographics/new promo efforts. Lidoderm is priced at a WAC of $6.71/day following 5% & 5.4% price increases on 2/1/10 & 2/1/11, respectively." ENDP closed at $35 on Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: ReiterationPre-Market OutlookMarketsAnalyst RatingsCitigroup
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!